For decades, menopause research has focused on declining estrogen and the cascade of symptoms it brings—vasomotor changes, bone loss, mood shifts, and urogenital discomfort. While hormone therapy remains one cornerstone of management, a new dimension of research is emerging: the role of the microbiome.

As estrogen wanes, microbial communities in the gut, vagina, and urinary tract shift in composition and metabolic output—changes that may influence how women experience the transition. This IPA article explores the mechanisms underlying these microbiome changes, their intersection with menopause, and how modifying the microbiota may help rebalance the microbiome and improve menopause-related outcomes.

Menopause, in brief

Menopause—defined by the cessation of menstruation and the decline of ovarian hormone production—brings wide-ranging physiological changes. A transitional state typically occurring between ages 45 and 55, it is characterized by decreasing levels of estradiol and progesterone, altered ovarian function, and reduced systemic estrogen. Perimenopause, which can last several years, refers to the stage from when these signs are first observed and ends one year after the final menstrual period. Natural menopause is deemed to have occurred after 12 consecutive months without menstruation, with the following stage often described as postmenopause.

Gradual hormonal shifts contribute to vasomotor (automatic widening and narrowing of blood vessels that control body temperature) symptoms such as hot flashes and night sweats, as well as vaginal dryness and mood fluctuations.

These declines in circulating estrogens also contribute to longer-term risks such as osteoporosis, endometrial hyperplasia, obesity, cardiovascular disease, and certain cancers.   

The microbiome during menopause

Estrogen helps maintain mucosal integrity and supports lactobacilli-dominated microbial ecosystems, especially in the gut and vagina. When estrogen levels drop, these protective species often decline, allowing for more diverse but less stable microbial communities. Evidence suggests that the composition of the microbiota could play a pivotal role in the onset or progression of some menopause-related clinical conditions. 

Gut microbiome

Declining estrogen alters bile acid metabolism and increases gut permeability, allowing translocation of endotoxins such as lipopolysaccharide that trigger low-grade inflammation. This inflammation contributes to metabolic dysregulation, mood changes, and increased bone resorption. 

In parallel, lower estrogen levels alter the activity of the estrobolome—a subset of gut microbes that regulate estrogen metabolism through the enzyme β-glucuronidase, which reactivates estrogens. When dysbiosis reduces β-glucuronidase activity, less estrogen is reabsorbed, further lowering systemic levels and worsening hormonal imbalance. Consistent with this mechanism, a recent study showed that a probiotic formula containing a bacterial strain having β-glucuronidase activity maintained circulating estradiol and estrone levels in peri- and postmenopausal women compared with placebo.

Probiotics may also enhance the effects of plant estrogens like isoflavones by helping gut microbes convert dietary phytoestrogens into bioactive compounds that modulate estrogen receptors. In a 12-month trial in postmenopausal women, a probiotic-enhanced isoflavone extract, along with mineral supplementation, improved estrogen metabolism and reduced bone loss more than supplementation alone. This interaction highlights their potential as beneficial adjuvants to existing menopause treatments.

Vaginal microbiome

In the vaginal microbiome, postmenopausal women typically experience a loss of protective lactobacilli species such as Lactobacillus crispatus and Lactobacillus jensenii, leading to higher pH, reduced lactic acid production, and increased susceptibility to infection or irritation.

These microbial shifts may contribute to systemic inflammation, weight gain, bone loss, and genitourinary symptoms commonly associated with menopause.

A 2023 review in Clinical Obstetrics & Gynecology reported that vaginal probiotics (for example, Lactobacillus crispatus or Lacticaseibacillus rhamnosus) increase lactic acid production and reduce vaginal pH, and may enhance microbiota responses to topical estrogen; however,  microbiome shifts do not uniformly translate to clinical symptom relief.

Mechanisms of probiotics

Probiotics exert beneficial effects through several mechanisms, including strengthening the gut barrier, producing bioactive metabolites, and regulating immune responses that reduce inflammation and support mucosal integrity. Probiotic strains typically colonize the gut only temporarily, so sustained benefits likely require ongoing use. 

A number of randomized studies have investigated probiotic use in postmenopausal women. 

The following sections review current evidence on the role of dysbiosis and the potential benefits of probiotics for major menopausal comorbidities.

Bone health 

Bone is a dynamic organ that remodels continuously through coordinated signals among bone, immune, hormonal, and neural systems. Estrogen loss disrupts this balance, accelerating bone resorption and reducing bone formation, leading to osteoporosis. 

The gut microbiota may influence bone metabolism by modulating immune activity, enhancing calcium absorption, and producing short-chain fatty acids (SCFAs) that support bone density. 

Animal studies show that probiotic modulation of the gut microbiota produces beneficial effects for bone health across multiple bacterial strains. 

Clinical studies support these benefits. A 2024 meta-analysis of 12 randomized controlled trials involving 1,183 postmenopausal women found that probiotic supplementation significantly increased bone mineral density in the lumbar spine and hip and reduced bone resorption markers, with the greatest benefit seen in women with osteopenia.

Type 1 endometrial hyperplasia

Type 1 endometrial hyperplasia—a precancerous condition—may become more common after menopause because declining progesterone and relative estrogen excess—whether from body fat, hormone therapy, or gut microbial metabolism—promote unopposed endometrial growth. 

At the same time, menopause-related shifts in vaginal and uterine microbiota, such as reduced lactobacilli and higher vaginal pH, may further favor inflammation and colonization by pathogenic bacteria that contribute to endometrial abnormalities. While there is limited clinical evidence in women, an in vitro study has shown that Lacticaseibacillus rhamnosus reduces pH levels by producing lactic acid and other organic acids, thus preventing endometrial infections by inhibiting some microbial species. 

Obesity 

Weight gain and increased body fat accumulation during menopause appear to result from several factors, including hormonal imbalance. Increased adiposity is associated with gut dysbiosis, characterized by a higher Firmicutes/Bacteroidetes ratio and greater endotoxin (lipopolysaccharide) production, which promotes systemic inflammation and further fat accumulation. This dysbiosis may also impair microbial metabolism of estrogen-like compounds such as isoflavones, further contributing to metabolic dysfunction and weight gain in postmenopausal women. 

A systematic review found that probiotics often reduce BMI, waist, or visceral fat in obesity in adults. Among overweight or obese postmenopausal women, more specifically, a recent systematic review and meta-analysis found that probiotic supplementation did not impact adiposity but led to modest, statistically significant improvements in insulin levels, insulin sensitivity, and markers of inflammation.

Cardiometabolic effects

Menopause increases cardiometabolic risk through hormonal decline, body compositional changes, and dysbiosis-driven changes in gut microbial metabolism that promote inflammation, insulin resistance, and dyslipidemia. Specific microbial species have been linked to these metabolic disturbances independently of body weight. 

Recent evidence suggests that probiotic supplementation may reduce this risk. In one study of obese postmenopausal women, 12 weeks of high-dose multispecies probiotic supplementation significantly improved vascular function and reduced inflammatory and endothelial dysfunction markers compared to placebo.

Evidence from studies not specific to menopausal women shows that probiotics may improve cardiovascular risk factors—such as cholesterol, blood pressure, inflammation, glucose, and BMI—but their effects depend on strain, dose, and individual factors. One proposed mechanism for the cardiometabolic benefits of probiotics is through enhanced production of SCFAs, which maintain gut barrier integrity and help regulate inflammation, glucose, lipid metabolism, and blood pressure.

A wider lens

A 2025 review of 39 studies involving 3,187 women examined probiotic interventions across the menopause transition. The results demonstrated that probiotics had positive effects on menopausal symptoms, urogenital health, and bone health, and may complement the efficacy of estriol and isoflavones.

In a meta-analysis of seven studies within the review, probiotics significantly improved overall menopausal symptoms—including vasomotor and psychological symptoms, vaginal dryness, and vaginal microbiome health—compared with placebo. Benefits were most frequently reported with Lacticaseibacillus rhamnosus, Limosilactobacillus reuteri, and Bifidobacterium longum species, alone or in multi-strain blends given orally or vaginally. However, findings are limited by high study bias, inconsistent probiotic strains and doses, and significant variation in menopausal populations and interventions.

In addition to supplements, a diet rich in prebiotic fibers, fermented foods, and polyphenol-rich foods supports a resilient microbiome, promoting beneficial bacteria, SCFA production, mucosal health, and reduced inflammation during menopause.

Takeaway

Disruptions in microbial balance are now recognized as a key feature of the menopause transitional period, intersecting with endocrine, immune, and metabolic systems. Reduced lactobacilli populations and increased microbial diversity may contribute to higher rates of urogenital infection, insulin resistance, cardiovascular disease, and bone loss. Targeted probiotic supplementation aims to counter these effects by restoring microbial stability and lowering inflammation across mucosal sites. Although the evidence base is still developing—with most studies limited by small cohorts and variable strain selection—several well-designed trials demonstrate benefits for vaginal health, metabolic parameters, and systemic inflammatory markers. The strength of evidence is moderate but growing, suggesting that probiotic therapy, while not a substitute for hormone therapy, lifestyle or diet, represents a promising adjunct to improve quality of life and reduce long-term health risks in menopausal women.

Key references